cas 1380089-99-5|| where to buy 1,1-Dimethylethyl (4S)-5,6-dihydro-1-methyl-6-oxo-4H-isoxazolo[5,4-d][2]benzazepine-4-acetate

Product Name:1,1-Dimethylethyl (4S)-5,6-dihydro-1-methyl-6-oxo-4H-isoxazolo[5,4-d][2]benzazepine-4-acetate

IUPAC Name:tert-butyl 2-[(7S)-3-methyl-9-oxo-5-oxa-4,8-diazatricyclo[8.4.0.0²,⁶]tetradeca-1(14),2(6),3,10,12-pentaen-7-yl]acetate

Packing Unit	Available Stock	Price($)	Quantity

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1380089-99-5 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:1380089-99-5; Molecular Formula:C18H20N2O4; Melting Point:-; Smiles Code:CC=1C=2C=3C(C(=O)N[C@@H](CC(OC(C)(C)C)=O)C2ON1)=CC=CC3; Density:

: Catalog Number:CM1074974; Molecular Weight:328.37; Boiling Point:; MDL No:; Storage:

: Isoxazoles; Isoxazole is a liquid heterocyclic compound C3H3NO isomeric with oxazole and having a penetrating odor like that of pyridine. Isoxazoles belong to an important class of five-membered aromatic heterocycles containing two electronegative heteroatoms, nitrogen and oxygen, in a 1,2-relationship and three regular sp2 carbon atoms. These molecules are found to be key components in various synthetic products in daily use and also present as a pharmacophore essential for biological activity in many drugs and bioactive natural products. In addition, isoxazoles have demonstrated their ability to exhibit hydrogen bond donor/acceptor interactions with a variety of enzymes and receptors.

: Pelabresib; MorphoSys’ phase 3 study of Pelabresib in myelofibrosis demonstrates statistically significant improvement in spleen volume reduction and strong positive trend in symptom reduction.
Pelabresib (CPI-0610) is an investigational selective small molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain (BET) proteins to decrease the expression of abnormally expressed genes in cancer. MorphoSys intends to submit for approval in the U.S. and Europe in mid-2024.